NCT02847481

Brief Summary

This is a randomized pilot study to characterize engraftment of a donor's microflora onto patients with Irritable Bowel Syndrome with diarrhea following fecal microbiota transplantation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started May 2016

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 12, 2016

Completed
16 days until next milestone

First Posted

Study publicly available on registry

July 28, 2016

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 5, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 5, 2018

Completed
Last Updated

December 23, 2019

Status Verified

December 1, 2019

Enrollment Period

2.3 years

First QC Date

July 12, 2016

Last Update Submit

December 20, 2019

Conditions

Keywords

Fecal Microbiota Transplantation

Outcome Measures

Primary Outcomes (1)

  • stable engraftment of donor microbiota

    Stable engraftment will be defined with the Jensen-Shannon Divergence (JSD) between the bacteria community measured in the donor and recipient. Engraftment scores will be defined by the ratio between the JSD in comparison between the recipient and donor and the recipient and other healthy donors not providing material for their FMT.

    10 weeks

Study Arms (4)

fecal microbiota transplantation

EXPERIMENTAL

fecal microbiota transplantation

Procedure: fecal microbiota transplantation

placebo fecal microbiota transplantation

PLACEBO COMPARATOR

placebo fecal microbiota transplantation

Drug: placebo fecal microbiota transplantation

FMT after antibiotic pretreatment v1

EXPERIMENTAL

fecal microbiota transplantation after antibiotic pretreatment

Procedure: fecal microbiota transplantationProcedure: FMT with antibiotic pre-treatment (v1)

FMT after antibiotic pretreatment v2

EXPERIMENTAL

fecal microbiota transplantation after antibiotic pretreatment

Procedure: fecal microbiota transplantationProcedure: FMT with antibiotic pre-treatment (v2)

Interventions

fecal microbiota transplantation

FMT after antibiotic pretreatment v1FMT after antibiotic pretreatment v2fecal microbiota transplantation

placebo fecal microbiota transplantation

placebo fecal microbiota transplantation

FMT with antibiotic pre-treatment (v1)

FMT after antibiotic pretreatment v1

FMT with antibiotic pre-treatment (v2)

FMT after antibiotic pretreatment v2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • IBS with diarrhea

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States

Location

Related Publications (1)

  • Singh P, Alm EJ, Kelley JM, Cheng V, Smith M, Kassam Z, Nee J, Iturrino J, Lembo A. Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D. Gut Microbes. 2022 Jan-Dec;14(1):2020067. doi: 10.1080/19490976.2021.2020067.

MeSH Terms

Conditions

Irritable Bowel Syndrome

Interventions

Fecal Microbiota Transplantationmyotrophin

Condition Hierarchy (Ancestors)

Colonic Diseases, FunctionalColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

Biological TherapyTherapeutics

Study Officials

  • Anthony Lembo, MD

    Beth Israel Deaconess Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Medicine

Study Record Dates

First Submitted

July 12, 2016

First Posted

July 28, 2016

Study Start

May 1, 2016

Primary Completion

August 5, 2018

Study Completion

August 5, 2018

Last Updated

December 23, 2019

Record last verified: 2019-12

Locations